ReviewNature reviews. Neurology2014
The emerging agenda of stratified medicine in neurology.
Review in Nature reviews. Neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Types and Concentrations of Blood-Based Biomarkers in Adults With Peripheral Neuropathies: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.Human brain mapping · 2016Trial
- Identification of predictive subphenotypes for clinical outcomes using real world data and machine learning.Nature communications · 2025Article
- Pre-Molecular Assessment of Self-Processes in Neurotypical Subjects Using a Single Cognitive Behavioral Intervention Evoking Autobiographical Memory.Behavioral sciences (Basel, Switzerland) · 2022Article
- Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease.Brain : a journal of neurology · 2021Article
- Nitric oxide and the brain. Part 1: Mechanisms of regulation, transport and effects on the developing brain.Pediatric research · 2021Review
- Contested futures: envisioning "Personalized," "Stratified," and "Precision" medicine.New genetics and society · 2019Article
- Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS.Neurology(R) neuroimmunology & neuroinflammation · 2018Article
- Early-Life Epilepsies and the Emerging Role of Genetic Testing.JAMA pediatrics · 2017Article
- Practices and views of neurologists regarding the use of whole-genome sequencing in clinical settings: a web-based survey.European journal of human genetics : EJHG · 2017Article
- Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value.Journal of personalized medicine · 2016Article
- A new neuroinformatics approach to personalized medicine in neurology: The Virtual Brain.Current opinion in neurology · 2016Review
- Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research.PharmacoEconomics · 2016Article
- Service users' and carers' views on research towards stratified medicine in psychiatry: a qualitative study.BMC research notes · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Stratified medicine can reduce the costs of neurological care, bringing benefits to both patients and physicians. The availability of routine genetic testing, new biomarkers and advanced imaging, as well as new technologies for patient-centred data collection, has expanded the potential for patient stratification. Several neurology subspecialities, including stroke, epilepsy and behavioural neurology, have already applied stratification for disease prognosis, optimization of disease management and reduction of treatment-related adverse events. Stratification approaches could improve the cost-effectiveness of neurological care that involves treatments with high costs or risks of adverse reactions, as well as guide the use of emerging, highly individualized therapies. There are still major challenges in the development of clinically actionable stratification concepts, and practical barriers can limit adoption of these concepts into clinical practice. However, improved technologies and disease understanding are making more precise stratification practical. We believe that neurologists should become leaders in the development and validation of these practices, and that use of these approaches should be part of a broader strategy for addressing both the growing needs of an ageing population and the rising pressures for rapid improvements in the cost-effectiveness of therapeutics.
Indexed as
Identifiers
24323053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.